Vigil Neuro
Leah Gibson is a communications and investor relations professional with extensive experience across various companies in the biotechnology and renewable energy sectors. Currently serving as Vice President of Investor Relations & Communications at Vigil Neuroscience since June 2023, Leah previously held multiple roles at Cybin Inc. from November 2021 to June 2023, including Vice President of Investor Relations & Strategic Communications and Vice President of Investor Relations. From March 2020 to November 2021, Leah led Investor Relations at Theratechnologies Inc. and worked at Vertex Pharmaceuticals in investor relations from October 2013 to March 2020. Prior experience includes serving as the Investor Relations & Corporate Communications Director at Satcon Technology Corporation and as an Investor Relations & Financial Communications Consultant at Sharon Merrill Associates. Early roles included positions as Investor Relations Manager and Coordinator at BearingPoint. Leah holds a BA in Public Relations, Marketing, and Media Management from San Diego State University and also attended Suffolk University.
This person is not in any teams
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.